Loading
institutionsInstitution
IUCT Oncopole (Institut Universitaire du Cancer de Toulouse)
Toulouse's cancer campus, joining the Institut Claudius Regaud and the university hospital, and a world leader in multiple myeloma research.
Also called: IUCT-OInstitut Claudius RegaudOncopole Toulouse
Overview
The IUCT Oncopole opened in 2014 on the site of the former AZF chemical plant, combining the Institut Claudius Regaud (a UNICANCER centre founded in 1923) with the oncology services of the CHU de Toulouse, next to the Cancer Research Center of Toulouse (CRCT) and Pierre Fabre's research centre. Its haematology group (Michel Attal, Hervé Avet-Loiseau) anchors the Intergroupe Francophone du Myélome, whose trials established transplant, lenalidomide maintenance and minimal residual disease as pillars of myeloma care. Other strengths are melanoma, gynaecological and head and neck cancers, radiotherapy and an early-phase unit. Patients from Occitanie access molecular tumour boards, CAR-T and bispecifics through the site.
Location
Toulouse, FR
Type
cancer center · Université de Toulouse
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#234 · 26 points (0 Newsweek + 0 NCI + 26 from 13 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-15.
Matched to Institut Claudius Regaud, including child institutions. 232 works · 3,172 citations · 57% open access · 18% clinical trials · 1% reviews.
Oncology works per year
492022
642023
482024
402025
312026
Most works
- Thomas Filleron29 works
- Florence Dalenc25 works
- Laurence Gladieff22 works
- Christelle Lévy18 works
- Carlos Gomez‐Roca16 works
- Anthony Gonçalvès16 works
- Jean‐Sébastien Frenel16 works
- Jean‐Pierre Delord15 works
- Alexandra Léary14 works
- William Jacot14 works
Most cited
- Multiple myeloma (IFM)
- Early-phase trials
- Melanoma
- Radiotherapy
- Cancer Research Center of Toulouse
Jean-Pierre Delord
Administrator of the GCS (Groupement de Coopération Sanitaire)
Medical oncologyEarly-phase clinical trialsHead and neck cancer
Medical oncologist who leads the IUCT Oncopole cooperation group in Toulouse and runs early-phase cancer drug trials.
Michel Attal
Haematologist and Director General, IUCT Oncopole, Toulouse
Multiple myelomaAutologous stem-cell transplantationIntergroupe Francophone du Myélome trials
French haematologist whose trials established autologous stem-cell transplantation for myeloma in the 1990s and, in IFM 2009, showed that transplant still adds benefit in the era of lenalidomide, bortezomib and dexamethasone.
Similar pages
- IdeaOutcome-based annuity payments for potentially curative one-time therapies
Shares Ciltacabtagene autoleucel, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, CAR-T cell therapy.
- TrialA Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Ind
Shares Teclistamab, Ciltacabtagene autoleucel, CAR-T cell therapy, Multiple myeloma.
- InstitutionComprehensive Cancer Center Mainfranken, University Hospital Würzburg
Shares Teclistamab, Ciltacabtagene autoleucel, Bispecific antibodies, CAR-T cell therapy.
- TrialA Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
Shares Ciltacabtagene autoleucel, CAR-T cell therapy, Multiple myeloma.
- TrialA Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
Shares Ciltacabtagene autoleucel, CAR-T cell therapy, Multiple myeloma.
- InstitutionIRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola
Shares Teclistamab, Bispecific antibodies, CAR-T cell therapy, Multiple myeloma.
- IdeaPlan the second CAR-T target before the first one is lost
Shares Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, CAR-T cell therapy, Multiple myeloma.
- InstitutionCentre Antoine Lacassagne
Shares UNICANCER, Head and neck squamous cell carcinoma, IMRT / IGRT (modern external beam), Melanoma.
cancers
fronts
technologies
drugs
ApprovedCAR-T (BCMA)
Ciltacabtagene autoleucel · Carvykti
ApprovedBispecific T-cell engager (BCMA×CD3)
Teclistamab · Tecvayli